Simcyp® PBPK Simulator
Streamlines drug development by using PBPK modeling to predict drug behavior in virtual populations, optimize…
CertaraJanuary 22, 2021
How drug developers can avoid these common mistakes to secure a deal
Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…
CertaraJanuary 21, 2021
Making your biotech program investor-ready
Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…
CertaraJanuary 21, 2021
An Introduction to Asset Evaluation for Emerging Biotech Companies
Emerging biotech companies sometimes lack all of the experience, expertise, or financial capital to successfully…
CertaraJanuary 21, 2021
“Where do I start?”: Strategies for selecting the first dose for human clinical trials
This guide to dose selection for first-in-human studies explains the conceptual framework, methods, and tools…
CertaraDecember 22, 2020
The Landscape of Emerging Randomized Clinical Trial Evidence for COVID-19 Disease Stages: A Systematic Review of Global Trial Registries
Alison Dillman,1 Michael J Zoratti,2 Jay JH Park,3 Grace Hsu,2 Louis Dron,2 Gerald Smith,2 Ofir Harari,2 Craig R Rayner,4 Noor-E Zannat,2 Alind Gupta,2 Eric Mackay,5 Paul…
CertaraDecember 22, 2020
Be Honest, Be Reliable, Be Human: Insights from a Global Drug Development Expert
One of the most exciting things about working in the pharmaceutical industry is the ability…
CertaraDecember 16, 2020
Certara Announces Pricing of its Upsized Initial Public Offering
PRINCETON, NJ.— December 10, 2020 – Certara, Inc. (“Certara”), a global leader in biosimulation, today…
CertaraDecember 10, 2020
Certara’s Phoenix software supports training of the next generation of the pharmacometricians in China
The Pharmacy department of the Shanghai Chest Hospital is dedicated to developing and applying model-informed…
CertaraDecember 3, 2020
Mechanistic model-informed discovery & development of bispecific antibodies for immuno-oncology: It takes 2 to tango
More than 50 bispecific antibodies are in oncology clinical development with a large diversity in…
CertaraDecember 2, 2020
